$7.69
+0.16 (+2.12%)
Open$7.62
Previous Close$7.53
Day High$7.75
Day Low$7.52
52W High$33.83
52W Low$5.67
Volume—
Avg Volume22.0K
Market Cap50.39M
P/E Ratio—
EPS$-7.08
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
+4.4% upside
Current
$7.69
$7.69
Target
$8.03
$8.03
$5.28
$8.03 avg
$9.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.19M | 11.47M | 10.10M |
| Net Income | 876.0K | 905.7K | 740.1K |
| Profit Margin | 7.2% | 7.9% | 7.3% |
| EBITDA | 1.90M | 1.88M | 1.67M |
| Free Cash Flow | 486.5K | 519.3K | 559.1K |
| Rev Growth | +7.7% | +14.6% | +19.0% |
| Debt/Equity | 1.27 | 1.35 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |